Skip to main content
SpringerLink
Log in

Immunological analysis and clinical effects of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion

  • Published:
Biotherapy

Abstract

Twenty effusions in sixteen patients with malignant peritoneal and/or pleural effusions were treated with intracavitary injection of lentinan. Lentinan was injected at a dosage of 4 mg/week for 4 weeks. In total, sixteen (80%) of twenty lesions demonstrated clinical responses. Performance status was improved in seven patients. The average survival time in responders was 129 days, while, in non-responders, it was 49 days. Serious toxicities were not observed.

NK activity of PBMC significantly decreased after lentinan injection. NK activity of PEC in responders was augmented significantly. Anti-Daudi and lymphokine activated killer activity were also augmented or maintained after lentinan injection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Torisu M, Katano M, Kimura Y, Itoh H, Takesue M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery 1983; 357–64.

  2. Yasumoto K, Miyazaki K, Nagashima A, Ishida T, Kuda T, Yano T, Sugimachi K, Nomoto K. Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer. Cancer Res 1987; 47: 2184–7.

    Google Scholar 

  3. Bast RC, Berek JS, Obrist R, Griffiths CT, Berkowitz RS, Hacker NF, Parker L, Lagasse LD, Knapp RC. Intraperitoneal immunotherapy of human ovarian carcinoma with corynebacterium parvum. Caner Res 1983; 43: 1395–401.

    Google Scholar 

  4. Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by polysaccharides from lentinus edodes (Berk.) Sing Nature 1963; 222: 687–8.

    Google Scholar 

  5. Chestermann H, Heywood R, Allen TR, Street AE, Edmondoson NA, Prentice DE. The intravenous toxicity of lentinan to the beagle dog. Toxicol Lett 1981; 9: 87–90.

    Google Scholar 

  6. Hamura J, Rollinghoff M, Wagner H. Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvantsof the b(1–3) glucan-type lentinan and its analogues. Immunology 1980; 39: 551–9.

    Google Scholar 

  7. Jeannin JF, Lagadec P, Pelletier H, Risser D, Olsson NO, Chihara G, Martin F. Regression induced by lentinan, of peritoneal carcinomatoses in a model of colon cancer in rat. Int J Immunopharmaco 1988; 10: 855–61.

    Google Scholar 

  8. Taguchi T, Furue H, Kimura T, Kondo T, Hattori T, Ito I, Ogawa N. End-point result of a randomized controlled study on the treatment of gastrointestinal cancer with a combination of lentinan and chemotherapeutic agents. In: Tsubura, E., Urushizaki, I. & Aoki, T., eds Rationale of biological response modifiers in cancer therapy Amsterdam: Excerpta Medica, 1985: 151–66.

    Google Scholar 

  9. WHO Handbook for Reporting Results of Cancer Treatment. World Health Organization. Genova 1979.

  10. Uchida A, Micksche M. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK-432. JNCI 1983; 71: 673–80.

    Google Scholar 

  11. Hamuro J, Chihara G. Lentinan, a T-cell-oriented immunopotentiator. Its experimental and clinical applications and possible mechanism of immune modulation. Immunomodulation agents and their mechanism (ed. Fenichel RL & Chirigos MA.) Marcel Dekker Inc., New York and Basel, 1984: 409–35.

    Google Scholar 

  12. Haba S, Hamaoka T, Takatsu K, Kitagawa M. Selective suppression of T-cell activity in tumor-bearing mice and its improvement by lentinan, a potent anti-tumor polysaccharide. Int. J. Cancer 1976; 18: 93–104.

    Google Scholar 

  13. Miyokoshi H, Aoki T. Acting mechanisms of lentinan in human-II. Enhancement of non-specific cell-mediated cytotoxicity as an interferon inducer. Int J Immunopharmac 1984; 6: 373–9.

    Google Scholar 

  14. Herlyn D, Kaneko Y, Powe J, Aoki T, Koprowski H. Monoclonal antibody-dependent murine macrophage mediated cytotoxicity against human tumors is stimulated by lentinan. Jpn. J Cancer Res 1985; 76: 37–42.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The Second Department of Surgery, Yamaguchi University School of Medicine, Kogushi 1144, 755, Ube City, Yamaguchi, Japan

    Masaaki Oka, Shigefumi Yoshino, Shoichi Hazama, Kouji Shimoda & Takashi Suzuki

Authors
  1. Masaaki Oka
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shigefumi Yoshino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shoichi Hazama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kouji Shimoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takashi Suzuki
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oka, M., Yoshino, S., Hazama, S. et al. Immunological analysis and clinical effects of intraabdominal and intrapleural injection of lentinan for malignant ascites and pleural effusion. Biotherapy 5, 107–112 (1992). https://doi.org/10.1007/BF02171695

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02171695

Key words

Search

Navigation